A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease
- PMID: 34688375
- DOI: 10.1016/S2468-1253(21)00367-8
A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease
Conflict of interest statement
DJL has served as a consultant for AbbVie, Abgenomics, Boehringer Ingelheim, Celgene, Janssen, Palatin Technologies, Pfizer, Prometheus Biosciences, and Takeda; received educational grants from AbbVie, Janssen, and Takeda; received a research grant from Kenneth Rainin Foundation; participated on the data safety monitoring board of WuXi; and received speaking honoraria from the GI Health Foundation, Academic CME, and Integrity CME. WA declares no competing interests.
Comment on
-
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014. doi: 10.1016/S2468-1253(21)00312-5. Epub 2021 Oct 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34688373 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical